InvestorsHub Logo

~S.B.A.~

02/02/13 9:08 AM

#53454 RE: zoomboom #53445

Michael j Fox funded AMBS preclinicals with a grant.

Dominion Capital just increased their investment by 230% 2 days ago with 1.4 added to the initial 600k for a lump sum of 2million convertible, which can be exercised in may 2013.

Keep in mind last 10q as of sept 30 the accounting period ended. Old figures, old information, and not relevant, due to 4 month margin. In those 4 months funding occurred (2 million) and AMBS still has the opportunity to pull from their 10 million by p/e. To say their is no cash is irresponsible and reckless. Using outdated information in not just irrelevant, but deceitful.

No matter what, the float is locked and evidence of low volume makes that case. Educating investors was our groups goal and we have now marched into an interesting part of the game. We are at checkmate. This was all planned and the checkmate has worked and continue to work once the PR breaks the game is won and many will win. Realize that this is a game and we are at checkmate bc of knowledge and the DD we gave to the common investor.

Knowledgeable, confident, and "know what they own" is the investor who holds real shares of Amarantus.

Checkmate.....next move is the endgame.

zoomboom

02/16/13 4:19 PM

#58770 RE: zoomboom #53445

Building value from a solid foundation



The data the Company released recently related to our MANF program in Parkinson’s disease is groundbreaking and first of its kind in the Parkinson’s space. Our Chief Scientific Officer, Dr. John Commissiong, presented the data at the OneMedForum 2013 Healthcare Conference, and showed a significant positive impact in every data category, thus supporting advancing MANF in both Investigational New Drug (“IND”)- enabling studies and human clinical studies.


the future has never looked brighter for Amarantus. We have unambiguous data supporting MANF’s further development in our lead Parkinson’s disease indication, we now have rights to seven diagnostic blood tests in significant markets, and our MANF asset continues to make progress in secondary indications. We are looking forward to an exciting 2013 for the Company and its shareholders.

source:
http://www.thechairmansblog.com/gerald-commissiong/2013-01/onwards-and-upwards-building-value-from-a-solid-foundation.html